InMed Pharmaceuticals Profile

USD 0.02  3.17%

InMed Pharmaceuticals Summary

InMed Pharmaceuticals (IMLFF) is traded on OTC Market in USA. It is located in 409 Granville Street and employs 6 people. The company currently falls under 'Small-Cap' category with current market capitalization of 109.35 M. InMed Pharmaceuticals has 113.84 M outstanding shares. INMED PHARMACEUTI has accumulated about 10.49 M in cash with (3.27 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.07.
Check InMed Pharmaceuticals Probability Of Bankruptcy

Target Price Odds Analysis

Odds Below 0.65HorizonTargetOdds Above 0.65
?%30 days 0.65 ?%
Based on normal probability distribution, the odds of InMed Pharmaceuticals to move above current price in 30 days from now is about 0.0% (This InMed Pharmaceuticals probability density function shows the probability of InMed Pharmaceuticals Stock to fall within a particular range of prices over 30 days) .

Key Fundamentals

InMed Pharmaceuticals Against Markets

Current Ratings

InMed Pharmaceuticals 30 Days Performance Scores
Risk Adjusted
Performance Score (0 to 100)
Chance of
Financial Distress (0 to 100%)
Equity ratings for InMed Pharmaceuticals are calculated dynamically based on Macroaxis scoring framework. Click here to learn more
InMed Pharmaceuticals Inc., a pre-clinical stage biopharmaceutical company, researches and develops novel and cannabinoid-based therapies. InMed Pharmaceuticals Inc. was incorporated in 1981 and is based in Vancouver, Canada. InMed Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in USA and traded on OTC Market. more
NameInMed Pharmaceuticals
CEOCraig SchneiderView All
Macroaxis Advice
InstrumentUSA Stock View All
Business Address409 Granville Street
ExchangeOTC Market
Contact Number604 669 7207
CurrencyUSD - US Dollar

Diversify with InMed Pharmaceuticals

Build Optimal Portfolios
Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations when you add InMed Pharmaceuticals to your portfolio


InMed Pharmaceuticals Corporate Directors
Andrew Hullh Director
Andrew Hull Director
William Garner Director
Please also check Risk vs Return Analysis. Please also try Equity Analysis module to research over 250,000 global equities including funds, stocks and etfs to find investment opportunities.